A 72-year-old woman with myasthenia gravis is admitted for acute exacerbation with severe generalized weakness, ptosis, and respiratory compromise (FVC 1.2 L, RR 28/min). She is on pyridostigmine 60 mg QID at home. In the ICU, she is intubated and sedated. On day 3, her physicians plan to wean sedation and assess her neuromuscular status. Which of the following is the most appropriate strategy regarding her cholinergic medication during ICU management?

Explanation

## Clinical Context: Myasthenia Gravis Exacerbation The patient has **myasthenic crisis** — acute decompensation requiring mechanical ventilation. The key decision is: how to manage cholinergic therapy in an intubated, sedated patient? ## Why Discontinue Cholinergic Drugs During Mechanical Ventilation **Key Point:** In mechanically ventilated patients, cholinergic drugs (anticholinesterases) should be **withheld** because: 1. **Paralysis from sedation masks symptoms** — you cannot clinically assess weakness, fasciculations, or cholinergic toxicity in a sedated, paralyzed patient. 2. **Risk of cholinergic crisis** — overdose causes bronchospasm, bronchorrhea, and muscle fasciculations that are dangerous in an intubated patient and difficult to detect. 3. **Mechanical ventilation bypasses the need** — the ventilator supports respiration; anticholinesterases are not needed for oxygenation. 4. **Allows disease assessment** — discontinuing these drugs for 24–48 hours helps differentiate myasthenic crisis from cholinergic crisis when sedation is lightened. **High-Yield:** The standard approach is: - **During mechanical ventilation**: Hold anticholinesterases - **Upon weaning**: Restart pyridostigmine at lower doses (e.g., 30 mg Q4–6H) and titrate based on clinical response - **Avoid edrophonium**: Short half-life and risk of cholinergic crisis make it unsafe in acute settings ## Comparison of Anticholinesterases | Drug | Onset | Duration | Route | Use in Acute MG | |------|-------|----------|-------|------------------| | **Pyridostigmine** | 30–60 min | 3–8 hrs | PO, IV | Maintenance; avoid acute crisis | | **Edrophonium** | 30–60 sec | 5–10 min | IV only | Diagnostic test (Tensilon test) — NOT for treatment | | **Neostigmine** | 7–15 min | 2–4 hrs | IV, IM | Acute exacerbation (with atropine cover) | **Warning:** Edrophonium is primarily a **diagnostic agent** (Tensilon test) to confirm MG, not a therapeutic drug for acute crisis. Its short duration and risk of cholinergic crisis make it unsuitable for sustained therapy. ## Management Algorithm for MG Exacerbation ```mermaid flowchart TD A[Myasthenic crisis]:::outcome --> B[Intubate & mechanically ventilate]:::action B --> C[Discontinue anticholinesterases]:::action C --> D[Supportive care: sedation, paralysis if needed]:::action D --> E{Ready to wean sedation?}:::decision E -->|Yes| F[Restart pyridostigmine at lower dose]:::action E -->|No| G[Continue mechanical ventilation]:::action F --> H[Titrate based on clinical response]:::action H --> I[Assess for extubation readiness]:::action I --> J[Successful weaning]:::outcome ``` **Clinical Pearl:** If cholinergic crisis is suspected (fasciculations, bronchospasm, bradycardia), give **atropine** (not more anticholinesterase). If myasthenic crisis is suspected (persistent weakness despite anticholinesterases), give **IV immunoglobulin or plasmapheresis**. [cite:Harrison 21e Ch 378; KD Tripathi 8e Ch 11]